<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>13</Volume>
				<Issue>11</Issue>
				<PubDate PubStatus="epublish">
					<Year>2012</Year>
					<Month>11</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5353</FirstPage>
			<LastPage>5361</LastPage>
			<ELocationID EIdType="pii">27044</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity in preclinical models. Itplays pivotal roles in linking inflammatory immune responses and tumor progression and is a useful candidatein gene therapy of lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 (rhIL-18) inpatients with advanced cancer concluded that rhIL-18 can be safely given in biologically active doses to patientswith advanced cancer. Some viruses can induce the secretion of IL-18 for immune evasion. The individualcytokine activity might be potentiated or inhibited by combinations of cytokines. Here we focus on combinationaleffects of cytokines with IL-18 in cancer progression. IL-18 is an important non- invasive marker suspected ofcontributing to metastasis. Serum IL-18 may a useful biological marker as independent prognostic factor ofsurvival. In this review we cover roles of IL-18 in immune evasion, metastasis and angiogenesis, applicationsfor chemotherapy and prognostic or diagnostic significance.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Interleukin-18</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Angiogenesis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Immunotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">predictive marker</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27044_6705df2fdd7fecc566b13b6dbda8c7e3.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
